Viking Therapeutics
VKTXHealthcare · Biotechnology · US25.17USD-8.04%
StratDeckViking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Price · Past year
Loading chart…
Checks
- Fail: Price trending down The figures
- Not known: Sales growth not available
- Not known: Profit margin not available
- Pass: Analysts rate it a strong buy The figures
- Not known: Valuation not available
- Pass: Beat profit forecasts The figures
Share
Keep researching
Where next from VKTX
Other stocks you may like
Fundamentals
SEC EDGAR
Yahoo FinanceShowHide
What's happening?
VKTX is lagging Healthcare this month The figures
- 1D
- -8.04%
- 7D
- -11.72%
- 1M
- -14.74%
- 3M
- -32.12%
- 6M
- -28.49%
- YTD
- -28.45%
What is the market expecting?
Expected to make a loss, and analysts expect the price to rise The figures
Not ranked on value: this stock carries too few of the multiples to score against its sector.
Is the business delivering?
Met or beat profit forecasts in 1 of the last 4 quarters
Earnings by quarter
Latest quarter -128M · +30.3M on the quarter before · -62.5M on a year earlier
- -24.9MOct24-2.69M
- -35.4MFeb25-10.5M
- -45.6MApr25-10.2M
- -65.6MJul25-19.9M
- -90.8MOct25-25.2M
- -158MFeb26-66.9M
- -158MApr26-663K
- -128MJul26+30.3M
How does it compare?
Value rankingVKTX is not ranked on value
What happens next?
Reports next on 28 Oct, in 11 days
Daily market updates
Get the brief
Get an interesting stock pick, updates on the AI sector, information on the biggest movers of the day, and more, in the Monday, Wednesday and Friday email.